GlassScriptPhysician profile
Silvia Dominguez
NPI 1558335927
$23,951.08
in general payments reported to CMS, 2019-2025
64 companies · $636 in 2025
The $636 reported for 2025 was more than what 78% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $4,815 · 2022: $7,664 · 2023: $7,969 · 2024: $2,868 · 2025: $636.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $457.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,015.09 |
| Education | $456.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,792.25 | 2021-2025 | Tagrisso, Lynparza, Calquence |
| Exelixis INC. | $2,089.62 | 2021-2025 | Cabometyx |
| Glaxosmithkline, LLC. | $1,394.74 | 2021-2025 | Ojjaara, Zejula, Jemperli |
| Novartis Pharmaceuticals Corporation | $1,354.84 | 2021-2025 | |
| Janssen Biotech, INC. | $1,322.95 | 2021-2025 | Darzalex, Tecvayli, Imbruvica |
| Amgen INC. | $1,036.61 | 2021-2023 | Kyprolis, Lumakras, Blincyto |
| Daiichi Sankyo INC. | $896.02 | 2021-2024 | Enhertu, Injectafer |
| E.R. Squibb & Sons, L.L.C. | $889.83 | 2021-2024 | Opdivo |
| Merck Sharp & Dohme LLC | $881.24 | 2021-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Celgene Corporation | $849.91 | 2021-2024 | Reblozyl, Pomalyst, Opdualag |
| Eisai INC. | $848.90 | 2021-2024 | |
| Seagen INC. | $803.67 | 2021-2023 | Tukysa, Adcetris, Padcev |
| Genentech USA, INC. | $701.92 | 2021-2025 | Polivy, Lunsumio, Venclexta |
| Lilly USA, LLC | $670.46 | 2021-2024 | Verzenio, Jaypirca, Retevmo |
| Genzyme Corporation | $488.88 | 2021-2024 |
Show all 64 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Silvia Dominguez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.